Interleukin-12 receptor subunit beta 2 (IL12RB2)

Interleukin-12 receptor subunit beta 2 (IL12RB2) is a type I transmembrane protein that serves as the essential signaling component of the high-affinity interleukin-12 (IL-12) receptor complex. Upon heterodimerization with the IL12RB1 subunit, it binds the cytokine IL-12 and activates the JAK2/STAT4 signaling pathway, which is critical for the differentiation of naive T cells into T helper 1 (Th1) cells and the stimulation of interferon-gamma (IFN-gamma) production. This receptor plays a dual role in human health: it is vital for host defense against intracellular pathogens and acts as a tumor suppressor in various B-cell malignancies, yet its overactivation is implicated in chronic inflammatory and autoimmune diseases such as Crohn's disease and multiple sclerosis. Therapeutic interventions targeting IL12RB2 include recombinant IL-12 agonists designed to boost anti-tumor immunity and various inhibitors or ligand-blocking antibodies, such as ustekinumab, intended to mitigate pathological Th1-mediated inflammation. However, clinical application of IL-12 signaling modulation is often limited by significant safety concerns, including severe systemic cytokine-related toxicities and hepatotoxicity.

Other names

IL-12 receptor subunit beta-2IL-12R subunit beta-2IL-12R-beta-2Interleukin-12 receptor beta-2 chainIL12R2I12R2

Agonism of the IL-12 receptor complex (IL12RB1/IL12RB2) activates the JAK2/STAT4 pathway to promote Th1 differentiation and anti-tumor immune responses; Antagonism or ligand-blocking (e.g., via p40 subunit inhibition) prevents IL-12 binding to the receptor, thereby reducing pro-inflammatory cytokine production and dampening autoimmune responses.